Re: Rx Media Pharma 2011 Crack Indir
Sacha Weakland
AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ion-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. The company has been focused on using its proprietary ion-trap technology to develop new treatments of kidney and liver diseases that are focused on addressing unmet needs in the medical community. For more information, please visit: www.zspharma.com.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
Social media plays a crucial role in the pharmaceutical industry as a tool to communicate with customers, patients, and healthcare professionals. Pharma brands can now create meaningful relationships with patients to understand their experience, improve their quality of care, and provide correct information on products and medical devices.
Pharma social media marketing comes with specific challenges to the industry, as pharma social media must follow regulations, stay compliant, and ensure public health and safety. A strong pharma social media strategy is a great way to manage pharma social media guidelines and strengthen brand reputation and positioning.
Substantial regulatory oversight, disclosure laws, and many other regulatory guidelines and requirements oversee the pharma and healthcare industry. Safety and pharmacovigilance matters can appear on social media at any time. Therefore, monitoring the safety of prescription drugs and medical devices they develop and advertise online is imperative for brands to reduce risk and take action when needed.
Pharmaceutical brands must stay alert on social media to identify any potential adverse event or technical complaint regarding any products or medical devices marketed. Any brand in the pharma industry must stay compliant with FDA guidelines by reporting any potential side effects to the appropriate channel within the appropriate time frame.
Whether on social media or elsewhere, the FDA requires pharmaceutical brands to follow strict guidelines regarding how products, medical devices, and medical information can be presented and shared with the public. The FDA encourages pharma companies to use social media to communicate, collaborate, and share information that might benefit the safety and protection of public health.
As Instagram is owned by Facebook, both follow the same advertising policies. Prescription drug promotion is allowed on Facebook and Instagram with pre-approval and written permission from Meta. Facebook and Instagram restrict the type of content and to whom it can be advertised, such as age and country of origin, with a strong emphasis on non-misleading, non-negative, or non-unsafe advertising. Pharmaceutical brands need to complete a prescription drug advertiser application to qualify to advertise on Meta social media platforms.
Twitter restricts the advertisement of health and pharmaceutical products. Policies vary based on specific products and services and the country the campaign is targeting. Pharma brands must review Twitter requirements to make sure they stay compliant with Twitter regulations, as well as local regulations. To start advertising pharmaceutical products or services on Twitter, brands need to reach out to the Twitter team for permission.
Since Youtube is a Google platform, pharmaceutical brands must refer to Google healthcare and medical advertising policies. YouTube allows some pharma-related ads, depending on local regulations and type of content. Advertisements must follow industry regulations and local guidelines.
Reddit allows health, wellness, and pharmaceutical advertisements on its platform, but they are restricted as they must be compliant with current local regulations, guidelines, and industry standards. Over-the-counter FDA-approved pharmaceutical drugs and medical devices are permitted on Reddit, while prescription pharmaceutical drug advertisements are only allowed in Canada and the United States. All pharmaceutical ads on Reddit are subject to pre-approval by the Reddit team and pharma brands need to provide legitimate documentation when necessary.
Most social media platforms allow pharmaceutical companies to advertise on their platform, but there are a few exceptions. LinkedIn, Pinterest, and TikTok do not allow any online pharmaceutical advertisement on their respective platforms.
Regulations and guidelines make social media marketing for the pharmaceutical industry challenging. Pharma brands must have reliable social media moderation and social listening teams to stay compliant with industry regulations.
Social media has moved beyond being a fashionable word to one that is drawing renewed attention from the pharma and healthcare industries. The power of these tools and the impact that they can have not only on brand perception and, effectively, on sales, as well as the increasing interest of the regulators in social media is resulting in this shift. In addition, tools and technology and the growth of the data sciences industry have proven to be powerful enablers. As patient centricity becomes the cynosure of attention, the need to capture their views becomes necessary. Social media brings in a pragmatic component to clinical trials, supporting the world of evidence-based medicine (EBM). Patients themselves want to draw more informed decisions and want to be participants in the decision-making process on how their health is going to be managed.
It has been observed in studies that of the more than 74% of Internet users that engage on social media, 80% are looking for health information,1 with 90% of the younger media-savvy 18-to-24 year-olds2 claiming that they relied upon this source, using it twice as often as the more senior population. They shared health-related conversations and patient stories on diverse topics such as how someone coped with a chronic condition, views on diet and exercise, and their choice of physician.2 The most accessed online resources for health-related information included WebMD (56%) and Wikipedia (31%).3 Patients wanted doctors to actively share updates on the disease, new pipeline compounds, their experience with different drugs, etc., on social media and 60% claimed that they trusted what the doctors were posting.4 It becomes all the more important for healthcare professionals (HCPs) to share accurate information and timely updates with the patient community. It was not only patients who were leveraging social media, 60% of HCPs were also actively watching what their counterparts are sharing on health-related issues. Doctors themselves seemed to truly believe that social media is impacting the quality of care. Forty percent of patients also relied upon social media to assess how others were dealing with chronic conditions.2
There is a whole spectrum of social media services being leveraged by pharma and healthcare, ranging across listening and analytics, marketing, and engagement. Companies are designing geography-based social media strategies based on the audience that they are targeting. Novartis, for example, thus engages with the public for its brand Gilenya (the once-a-day pill developed to treat multiple sclerosis) through a dedicated handle on Twitter, @GILENYAGoUSOnly. The introduction section of this Twitter handle clearly calls out that it is only for a US audience and also sets forth other guidelines of interaction, such as the response window, how to share personal details, and also the discretion Novartis would practice in responding or not responding to certain tweets.13 Internally, for a pharma company, this means the need for increased harmonization in social media efforts across countries and regions, while staying compliant with local regulations. When it comes to listening, social media tends to be more porous and it no longer matters, for instance, where an adverse event (AE) was reported, as it can find interested audiences anywhere in the world. But engagement is a different world altogether, as it has to be contextualized to the specific user, geography, local regulations, and so on.
It has also been observed that in a study conducted on AE reported for Lipitor (atorvastatin) and Meridia (sibutramine) in the FDA Adverse Event Reporting System (FAERS) database and on AskaPatient.com (a patient-support group website), the majority of AE reports on social media came from a younger population and focused on milder AEs on AskaPatient.com, as compared to those reported in FAERS.16
Pharma companies need to be mindful of varying regulations on the advertising of branded prescription products, while defining their product promotion strategy. It is very important, therefore, that each company develops its own social media policy guidelines. It has been observed that 23% of pharma organizations do not have policies to address data security and privacy, whereas 31% of healthcare organizations do have healthcare policies in place.2 A review of the top 100 companies listed on the London Stock Exchange demonstrated that the top three social media-savvy pharma companies are Johnson & Johnson, GlaxoSmithKline, and Pfizer, respectively This becomes especially relevant when a company is marketing its products in multiple geographies, with varying local regulations. While this is acceptable in the U.S., advertising of branded prescription products is not accepted by many other countries.
aa06259810